Wells Fargo Maintains Overweight on Aerovate Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth maintains an Overweight rating on Aerovate Therapeutics (NASDAQ:AVTE) and keeps the price target at $35.

April 01, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Overweight rating on Aerovate Therapeutics with a $35 price target.
The reaffirmation of an Overweight rating and a $35 price target by a major financial institution like Wells Fargo is likely to instill confidence among investors and could lead to a positive short-term price movement for AVTE. The analyst's endorsement serves as a strong signal of the stock's potential value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100